Qualicaps® to Display ID-Capsule™ Technology at INTERPHEX Week Japan
GAINESVILLE, Fla. (June 6, 2019) – etectRx™ and Qualicaps® have extended their existing collaborative relationship to further develop the manufacturing and assembly processes for ID-Capsules and the ID-Cap™ System. In addition, the two companies will work collaboratively to explore markets for etectRx’s proprietary technology and expand applications for digital medicine.
This collaboration will include investigations into advanced capsule development, digital medicine capabilities, and supply chain applications in the U.S., Japan, and globally. Additionally, Qualicaps® will present the ID-Cap System at the 21st INTERPHEX Week Japan, the premier pharmaceutical technology meeting in Asia (held July 3-5, 2019 in Tokyo, Japan). Qualicaps® will showcase the ID-Capsule, the first technology of its kind in Japan for improving the traceability of capsule formulations of drug products from distribution through patient ingestion.
Harry Travis, CEO of etectRx, stated, “Qualicaps® has been an excellent technical partner for many years. We are very grateful for their past contributions and look forward to an expanded working relationship. We are now entering into a new phase of our partnership that allows us to collaboratively explore the vast market potential for etectRx’s core technology.”
Masaharu Mori, CEO of Qualicaps®, elaborated on the etectRx ID-Cap System, “This is a valuable device that provides several benefits to the various stakeholders within the pharmaceutical industry, particularly in that it has the potential to improve patient adherence to medications and assist in clinical research and development.”
Terms of the agreement were not released, but the companies expect to provide more information about the collaboration later this year.
etectRx™ is a privately held digital health company seeking to advance patient medication adherence and improve medication ingestion tracking technology. etectRx’s flagship product, the ID-Cap System, is an ingestible event marker that is comprised of a gelatin capsule containing a wireless ingestible sensor, which transmits signals to a wearable reader and then to a smartphone-based app and secure cloud-based server to enable reliable tracking of ingestion events.
etectRx submitted a premarket notification (510(k)) application with the U.S. Food and Drug Administration (FDA) for its ID-Cap System as an ingestible event marker in late 2018 and anticipates FDA clearance for marketing in 2019. The ID-Cap System is currently only available for investigational use in IRB-approved clinical studies. To learn more about etectRx, visit https://etectrx.eerx.staging.findsomewinmore.com/.
Qualicaps® has been contributing to health for over 120 years through the manufacture and supply of two-piece hard capsules and related equipment. The company has a global presence, with production facilities located in the USA, Canada, Japan, Europe (Spain and Romania) and Brazil. Qualicaps® provides value to its customers in terms of product and service quality, collaboration in scientific, technical and regulatory aspects, and flexibility to fulfill special product requirements. Qualicaps® is a wholly-owned subsidiary of Mitsubishi Chemical Holdings Corporation (MCHC) through its Life Sciences Institute (LSII). For more information, visit https://www.qualicaps.com/.
About INTERPHEX Week Japan
For more information about the 21st INTERPHEX Week and INTERPHEX Japan events, visit https://www.interphex.jp/en-gb.html.
Media Contact for etectRx:
Media Contact for Qualicaps®: